

[REDACTED]

Dear Sir/Madam

As a member, Pfizer has provided detailed comment to the Australian Self-Medication Industry (ASMI) association following review of the consultation paper on Appendix M. Rather than duplicating comment, Pfizer would like to confirm its alignment with the response ASMI have submitted on behalf of its members.

Pfizer has appreciated the opportunity to participate in the working groups, and values the efforts being undertaken to develop Appendix M and the guidelines, and are happy to be contacted regarding this should you wish to discuss with us further.

Regards

[REDACTED]



LEGAL NOTICE Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee(s) only. Access to this e-mail by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you are not an addressee, please inform the sender immediately. Pfizer Australia has its registered office at Level 15-18, 151 Clarence Street, Sydney, NSW, 2000